Pfizer's $10B Innovent Deal Boosts Cancer Drugs | Pharma and Biotech Daily

About this episode

The episode discusses Pfizer's $10 billion deal with Innovent Biologics and its implications for cancer drug development.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a landscape teeming with strategic partnerships, groundbreaking clinical trial results, regulatory shifts, and innovative therapeutic approaches that are redefining patient care and drug development. Pfizer's monumental $10 billion collaboration with Innovent Biologics stands out as a testament to the shifting dynamics of the oncology secto...

People in this episode

Host: Pharma and BioTech News

Topics covered

• Pfizer
• Innovent Biologics
• cancer drugs
• strategic partnerships
• clinical trials
• regulatory shifts
• therapeutic approaches

Keywords

• Pfizer
• Innovent Biologics
• cancer drugs
• strategic partnerships
• clinical trials
• oncology

Mentioned in this episode

Organizations: Pfizer, Innovent Biologics

Places: oncology sector

More episodes of Pharma and BioTech Daily

• Takeda's Zasocitinib Beats Sotyktu in Phase 3 Trial | Pharma and Biotech Daily · June 12, 2026 · 5 min
• Pfizer CEO Rethinks Germany Investments Amid Reform Concerns | Pharma and Biotech Daily · June 11, 2026 · 5 min
• Merck & Gilead's HIV Pill Breakthrough: Phase 3 Success! | Pharma and Biotech Daily · June 10, 2026 · 5 min
• Eli Lilly's Retatrutide Breakthrough: 30.3% Weight Loss Success | Pharma and Biotech Daily · June 9, 2026 · 5 min
• Pfizer & Chai AI Breakthrough: $1.675B Gilead Deal | Pharma and Biotech Daily · June 8, 2026 · 5 min
• Eli Lilly & Boehringer Cut $1B+ Investments in Germany | Pharma and Biotech Daily · June 5, 2026 · 5 min